# 60 Degrees Pharmaceuticals, Inc.: overview SXTP · Nasdaq · CIK 1946563 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sxtp.md) · [Financials](/companies/sxtp/financials.md) · [Filings](/companies/sxtp/filings.md) · [Insiders](/companies/sxtp/insiders.md) Latest reported revenue: [$207.9k](/filings/0001554855-26-001860.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001554855-26-001860). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [135](/filings/0001554855-25-002032.md) | [242 d](/filings/0001554855-26-000467.md) | [164](/filings/0001554855-26-001058.md) | [101](/filings/0001554855-26-001860.md) | [438](/filings/0001554855-25-002032.md) | [303 d](/filings/0001554855-26-000467.md) | [162](/filings/0001554855-26-001058.md) | [208](/filings/0001554855-26-001860.md) | | Gross margin | % | [17.4%](/filings/0001554855-25-002032.md) | [51.1% d](/filings/0001554855-26-000467.md) | [55.2%](/filings/0001554855-26-001058.md) | [50.4%](/filings/0001554855-26-001860.md) | [(22.9%)](/filings/0001554855-25-002032.md) | [60.2% d](/filings/0001554855-26-000467.md) | [47.1%](/filings/0001554855-26-001058.md) | [27.3%](/filings/0001554855-26-001860.md) | | Operating margin | % | [(1566.0%)](/filings/0001554855-25-002032.md) | [(854.7%) d](/filings/0001554855-26-000467.md) | [(1168.4%)](/filings/0001554855-26-001058.md) | [(1591.5%)](/filings/0001554855-26-001860.md) | [(531.4%)](/filings/0001554855-25-002032.md) | [(632.0%) d](/filings/0001554855-26-000467.md) | [(1292.5%)](/filings/0001554855-26-001058.md) | [(1092.4%)](/filings/0001554855-26-001860.md) | | Net margin | % | [(1596.4%)](/filings/0001554855-25-002032.md) | [(846.3%) d](/filings/0001554855-26-000467.md) | [(1147.4%)](/filings/0001554855-26-001058.md) | [(1717.7%)](/filings/0001554855-26-001860.md) | [(529.3%)](/filings/0001554855-25-002032.md) | [(474.2%) d](/filings/0001554855-26-000467.md) | [(1288.9%)](/filings/0001554855-26-001058.md) | [(1089.2%)](/filings/0001554855-26-001860.md) | | Diluted EPS | $ per share | [(2.92)](/filings/0001554855-25-002032.md) | not reported | [(6.25)](/filings/0001554855-26-001058.md) | [(5.01)](/filings/0001554855-26-001860.md) | [(0.66)](/filings/0001554855-25-002032.md) | not reported | [(1.28)](/filings/0001554855-26-001058.md) | [(0.90)](/filings/0001554855-26-001860.md) | | Free cash flow | $k | [(1,695) d](/filings/0001554855-25-002032.md) | [(1,638) d](/filings/0001554855-26-000467.md) | [(1,600)](/filings/0001554855-26-001058.md) | [(1,497) d](/filings/0001554855-26-001860.md) | [(2,119) d](/filings/0001554855-25-002032.md) | [(1,772) d](/filings/0001554855-26-000467.md) | [(2,772)](/filings/0001554855-26-001058.md) | [(2,232) d](/filings/0001554855-26-001860.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | [223](/filings/0001213900-24-028577.md) | [254](/filings/0001013762-25-003343.md) | [608](/filings/0001554855-26-000467.md) | [1,005](/filings/0001554855-26-000467.md) | | Gross margin | % | [(93.7%)](/filings/0001213900-24-028577.md) | [(87.1%)](/filings/0001013762-25-003343.md) | [36.7%](/filings/0001554855-26-000467.md) | [22.3%](/filings/0001554855-26-000467.md) | | Operating margin | % | [(784.2%)](/filings/0001213900-24-028577.md) | [(2032.8%)](/filings/0001013762-25-003343.md) | [(1599.0%)](/filings/0001554855-26-000467.md) | [(771.6%)](/filings/0001554855-26-000467.md) | | Net margin | % | [(2769.5%)](/filings/0001213900-24-028577.md) | [(1485.1%)](/filings/0001013762-25-003343.md) | [(1308.0%)](/filings/0001554855-26-000467.md) | [(732.5%)](/filings/0001554855-26-000467.md) | | Diluted EPS | $ per share | [(2.61)](/filings/0001213900-24-028577.md) | [(59.18)](/filings/0001013762-25-003343.md) | [(74.17)](/filings/0001554855-26-000467.md) | [(11.73)](/filings/0001554855-26-000467.md) | | Free cash flow | $k | not reported | [(4,601)](/filings/0001013762-25-003343.md) | [(5,752)](/filings/0001554855-26-000467.md) | [(6,989)](/filings/0001554855-26-000467.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sxtp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Kathmere Capital Management, LLC](/funds/1794543.md) | 2026-06-30 | $466.6k | 265,100 | | Added +120,417 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $39.4k | 22,362 | | New +22,362 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $31.0k | 17,639 | | New +17,639 | | [Kovack Advisors, Inc.](/funds/1728321.md) | 2026-06-30 | $26.4k | 15,000 | | New +15,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $25.6k | 14,551 | | Reduced −1,744 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $23.9k | 13,592 | | Reduced −17,818 | | [Walleye Capital LLC](/funds/1758720.md) | 2026-06-30 | $6.1k | 200,481 | | Unchanged | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $4.4k | 145,969 | | Unchanged | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $1.9k | 1,052 | | Reduced −804 | | [TORNO CAPITAL, LLC](/funds/1974312.md) | 2026-06-30 | $1.4k | 47,169 | | Unchanged | ## Recent filings [All 221 filings](/companies/sxtp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 08:00 ET | [8-K](/filings/0001213900-26-111864.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-111864 | | 2026-10-06 | 07:45 ET | [8-K](/filings/0001213900-26-106979.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-106979 | | 2026-09-14 | 16:06 ET | [8-K](/filings/0001213900-26-099702.md) | 8.01 Other events | 0001213900-26-099702 | | 2026-09-08 | 16:27 ET | [8-K](/filings/0001213900-26-098056.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-098056 | | 2026-08-14 | 15:34 ET | [10-Q](/filings/0001554855-26-001860.md) | Quarterly report, period 2026-06-30 | 0001554855-26-001860 | | 2026-08-06 | 16:07 ET | [8-K](/filings/0001213900-26-086136.md) | 5.07 Shareholder vote results | 0001213900-26-086136 | | 2026-08-04 | 16:44 ET | [8-K](/filings/0001213900-26-085235.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-085235 | | 2026-07-20 | 16:05 ET | [8-K](/filings/0001213900-26-079612.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-079612 | | 2026-07-09 | 16:05 ET | [8-K](/filings/0001213900-26-076715.md) | 8.01 Other events | 0001213900-26-076715 | | 2026-07-02 | 16:05 ET | [DEF 14A](/filings/0001213900-26-074961.md) | Proxy statement, period 2026-08-05 | 0001213900-26-074961 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001554855-26-000467.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b2959b1c-933b-44e9-b2e0-def442d6a48b) ## About the filer - CIK: 1946563 - Tickers: SXTP, SXTPW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 08:06 ET. No prices; not investment advice.